Intracellular molecules represent nearly half of the human proteome and provide an untapped reservoir of potential therapeutic targets. Intracellular proteins can be degraded by the proteasome into short, commonly 8–10 amino acid long, peptides that are presented on the cell surface in the context of major histocompatibility complex class I (MHC-I) molecules. T-cell receptor or T-cell receptor mimic (TCRm) antibodie can be used to target peptides bound to major histocompatibility complex class I (MHC-I) molecules on the cell surface. MHC/antigenic peptide complexes are good tools for antibody or TCR discovery.
Antibody discovery，TCR discovery：Immunization，Screening，Function Characterization
Binding asssay：ELISA，SPR, BLI
Pharmacokinetic：Quantitative ELISA
| Cat.No. | Product Name | Species | Tag |
|---|---|---|---|
| MHC-HM431 | HLA-A*0201 WT-1 (RMFPNAPYL) | Human | His-Avi |
Mammalian expression，Nature Post-translational modification ，High affinity.
Recombinant Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein was greater than 95% as determined by SEC-HPLC.
Immobilized Human HLA-A*0201 WT-1 (RMFPNAPYL) complex at 2ug/ml(100ul/Well).Dose response curve for Anti-WT1 complex mAb.with the EC50 of 193.9ng/ml determined by ELISA.
Please fill in the following information, we will contact you as soon as possible!
